US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,807.76

-17.2311-0.94%

Number of Gainers:7

Number of Losers:12

Number of Flat:- -

PE:- -

High:1,831.56

Open:1,825.61

Low:1,802.81

Close:1,824.99

Volume:60.23M

Turnover:4.96B

Market Cap:1.47T

Float Cap:1.44T

Loading ...

Pfizer (PFE) Bets Big on RSV and Cancer Care

NYSE Most Active Issues

NASDAQ New 52-Week Highs and Lows

Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study

Pfizer’s RSV Revaccination Trial Targets Durable Booster Revenue in High‑Risk Adults

AstraZeneca Advances Friday, Outperforms Market

Innovation is Driving a New Bull Market in Biotech. 16 Ways to Play It, from Our Roundtable Experts.

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week

MT Newswires Live

Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study

THOMSON REUTERS

Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma

Ocugen Wins Provisional Approval for Ocu400 in Bahamas Under LARTA Pathway

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in the Bahamas to Provide Ocu400 to Patients for Treatment of Retinitis Pigmentosa

THOMSON REUTERS

C4 Therapeutics Says Cemsidomide-Elranatamab Phase 1b Trial Clears 75 Μg Dose as Safe in Multiple Myeloma

Moderna (MRNA) Receives a Hold from Bernstein

AstraZeneca sBLA for Imfinzi combination accepted, granted Priority Review

AstraZeneca Gets US FDA Priority Review for Investigative Bladder Cancer Therapy

MT Newswires Live

INLIF Stock Is Trending: Here's Why it Skyrocketed Over 93% After Hours

Benzinga Earnings

Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/BK4568/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1807.7544,"timestamp":1790970048321,"preClose":1824.9855,"halted":0,"volume":60225786,"delay":0,"changeRate":-0.009442,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-17.231079,"latestTime":"10-02 15:40:48 EDT","open":1825.6097,"high":1831.557,"low":1802.8068,"amount":4958698552.717263,"amplitude":0.015754,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.847322,"peRate":47.020292,"turnoverRate":0.004341,"increases":7,"decrements":12,"flats":0,"marketCap":1470393414840,"floatMarketCap":1435391274640},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1831.557,"amplitude":0.015754,"preClose":1824.9855,"low":1802.8068,"pbRate":"4.847322","latestPrice":1807.7627,"volume":60227901,"delay":0,"open":1825.6097,"prevYearClose":1637.1339,"prevWeekClose":1903.4879,"prevMonthClose":1862.664,"prevQuarterClose":1862.664,"fiveDayClose":1903.4879,"twentyDayClose":1915.5433,"sixtyDayClose":1751.8207,"secType":"PLATE","market":"US","turnoverRate":0.004341,"peRate":47.020292,"marketCap":1470393414840,"floatMarketCap":1435391274640,"timestamp":1790970049629,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":7,"down":12,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670474940","title":"Pfizer (PFE) Bets Big on RSV and Cancer Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2670474940","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670474940?lang=en_us&edition=fundamental","pubTime":"2026-09-26 23:02","pubTimestamp":1790434935,"startTime":"0","endTime":"0","summary":"Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer Inc. is quietly building new pi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/pfizer-pfe-bets-big-on-rsv-and-cancer-care?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/pfizer-pfe-bets-big-on-rsv-and-cancer-care?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","LU1066053197.SGD","IE00BBT3K403.USD","BK4581","LU0058720904.USD","BK4550","LU1066051498.USD","LU0234572021.USD","LU0225771236.USD","IE0002270589.USD","LU0321505439.SGD","LU0306806265.USD","LU0289739699.SGD","LU0321505868.SGD","SG9999001176.USD","SGXZ57979304.SGD","BK4568","LU1894683264.USD","LU2596442595.SGD","LU1057294990.SGD","BK4592","BK4534","IE00B19Z3581.USD","LU0306807586.USD","SG9999002224.SGD","IE00B3T34201.USD","LU1883839398.USD","OZEM","IE00B19Z3B42.SGD","SG9999011175.SGD","LU0868494617.USD","LU0456855351.SGD","LU0985481810.HKD","PFE","IE00BLSP4239.USD","SG9999013999.USD","BK4588","IE000M9KFDE8.USD","LU1894683348.USD","BK4599","SG9999003800.SGD","LU0170899867.USD","BK4585","IE00BLSP4452.SGD","LU0225284248.USD","BK4533","BK4007","SG9999001176.SGD","SG9999002232.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670222014","title":"NYSE Most Active Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2670222014","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670222014?lang=en_us&edition=fundamental","pubTime":"2026-09-26 05:40","pubTimestamp":1790372400,"startTime":"0","endTime":"0","summary":"Nu Holdings Cl A              NU    52,825,762     13.59     0.03      0.22. Nike Cl B                    NKE    38,110,169     35.75    -0.24     -0.67. BitMine Immersion Techs     BMNR    31,474,128     27.56    -0.47     -1.68. Bank of America              BAC    28,362,710     56.70     0.67      1.20","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXO","LU0980610538.SGD","KBWB","APIE","IE000M9KFDE8.USD","LU1496350502.SGD","IYG","LU0211331839.USD","LU0106831901.USD","SAPH","LU1894683264.USD","SG9999002232.USD","LU1880398554.USD","LU1861558580.USD","SG9999002224.SGD","XLF","LU0058720904.USD","LU1791807156.HKD","FNCL","AADR","PATX","TFNS","BK4568","LU0203347892.USD","LU0306806265.USD","OZEM","SG9999001176.USD","CVY","IYF","LU1074936037.SGD","IE00BBT3K403.USD","LU2133065610.SGD","ARMH","DINT","DIVL","UYG","BK4547","BK4533","LU0289739699.SGD","LU0320765646.SGD","LU0321505868.SGD","BAC","LU1035773651.USD","VFH","BBUL","PATH","LU0208291251.USD","PFE","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670706429","title":"NASDAQ New 52-Week Highs and Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2670706429","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670706429?lang=en_us&edition=fundamental","pubTime":"2026-09-26 02:22","pubTimestamp":1790360520,"startTime":"0","endTime":"0","summary":"ARC Group Secs Acqn I        FJDIU       10.14         26,835. Gl X Genomics & Biotech      GNOM        70.83         11,765. GrShr 2x Long AMD Daily      AMDL        86.43      1,432,877. Invsc BS 2036 Mun Bd         BSMA        27.15          6,786. Leverage 2X Lg AMD Dly       AMDG       145.58         21,664","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0274383776.USD","BK4139","LU1989764748.USD","ILDR","QID","QMAR","BK4534","LU1852331112.SGD","NJAN","LU2456880835.USD","WISE","GNOM","TQQQ","LU2462591350.SGD","SQQQ","IE00BMPRXR70.SGD","SGXZ51526630.SGD","BK4512","BK4614","LU0174119429.USD","LU2360107168.USD","AMDG","LU0082616367.USD","LU2361044949.HKD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0390134368.USD","TQQY","TEK","BK4533","LU1989772923.USD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","GPIQ","LU2098885051.SGD","IE00BMPRXQ63.HKD","SAMD0main","LU2247934214.USD","AMDD","LU0642271901.SGD","03086","LU1804176565.USD","LU2054465674.USD","PSQ","QDEC","QQQX","FAI","IETC","LU1989764664.SGD","BK4529","IE00B1BXHZ80.USD","LU2355687059.USD","XNTK","SG9999014039.USD","BK4588","LU0719512351.SGD","LU1861215975.USD","IE00BN0W2W23.USD","QQQA","SMH","AMYY","LU0109391861.USD","LU2290526834.HKD","SG9999014021.USD","WDNA","LU0109392836.USD","03034","LU1880398471.USD","LU1064131342.USD","AMDY","LU2458330243.SGD","IDNA","LU0672654240.SGD","BK4605","LU0210536198.USD","LU0889565833.HKD","LU1267930730.SGD","LU2360106780.USD","LU2860962120.EUR","LU2242649171.HKD","SOXX","USXF","AMUU","IE00B5949003.HKD","IE00BMPRXN33.USD","AIQ","LU0348723411.USD","IE00BQXX3F31.USD","BK4612","LU0251132253.USD","LU2210150020.SGD","LU0198837287.USD","BK4585","SG9999001424.SGD","LU1861559042.SGD","BK4573","SG9999014013.SGD","AMDL","IE00BN0W2V16.EUR","BK4532","LU0823434740.USD","LU0823434583.USD","LU2458330169.SGD","SGXZ99366536.SGD","SMHX","IE00BN0W2T93.GBP","LU0320765059.SGD","LU1242518857.USD","LU2361045086.USD","SGXZ81514606.USD","07261","LU1951198990.SGD","QLD","BAI","QQQM","BK4566","IE0009356076.USD","LU1861558580.USD","BK4501","IE00BGHQF748.EUR","LGHT","CHPS","CNAV",".IXIC","SOXY","BK4543","LEGR","LU2108987350.USD","07568","NDAQ","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","LU0792757196.USD","BK4554","IE00BZ1G4Q59.USD","LU2361044865.SGD","LU0048584097.USD","BCDF","NDX","LU2461242641.AUD","BK4568","LU1880398554.USD","LU0823421333.USD","LU0056508442.USD","LU1242518931.SGD","GAMR",".HXC","LU1316542783.SGD","09834","LU2931357623.SGD","03455","LU2250418816.HKD","07522","BK4141","LU0889566641.SGD","TRFK","LU1861220033.SGD","PSI","LU1988902786.USD","LU2210149790.SGD","LU2095319765.USD","AMDS","AIS","QQQ","DAMD","BK4575","AMDW","LU0786609619.USD","BK4548","BK4551","IE0004445239.USD","SG9999014005.SGD","NJUL","02834","09086","LU1923623000.USD","MRNA","LU2417539215.USD","IE00BKVL7J92.USD","LU0133085943.USD","LU2265009873.SGD","MRNY","LU1951200564.SGD","AMDU","TTEQ","LU2089985449.USD","LU2896262040.SGD","AMDC","LU2236285917.USD","07266","LU1267930813.SGD","NAPR","LU0081259029.USD","AMD","LU2543165471.USD","LU1303367103.USD","LU1989772840.SGD","FTXL","MRNX","LU0979878070.USD","WUGI","LU1232071149.USD","LU0823421416.USD","LU0127658192.USD","NOCT","LU0708995401.HKD","LU2264538146.SGD","IE0001KFT4U8.USD","LU1803068979.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670426456","title":"Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2670426456","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670426456?lang=en_us&edition=fundamental","pubTime":"2026-09-26 00:31","pubTimestamp":1790353868,"startTime":"0","endTime":"0","summary":"Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is launching a new study to test ponsegromab in adults wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizer-targets-cancer-related-weight-loss-with-new-ponsegromab-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizer-targets-cancer-related-weight-loss-with-new-ponsegromab-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","BK4592","SG9999003800.SGD","IE0002270589.USD","SG9999001176.USD","LU1883839398.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU0234572021.USD","IE00BLSP4239.USD","BK4581","LU0225284248.USD","LU0321505439.SGD","PFE","LU1023059063.AUD","SG9999001176.SGD","BK4533","SG9999011175.SGD","LU0868494617.USD","BK4007","BK4550","LU0122379950.USD","LU1066051498.USD","SGXZ57979304.SGD","BK4534","BK4599","BK4568","IE00B19Z3581.USD","LU0289739699.SGD","SG9999002232.USD","BK4588","LU1894683264.USD","LU0306806265.USD","LU1066053197.SGD","LU2596442595.SGD","LU0321505868.SGD","LU0456855351.SGD","LU0985481810.HKD","LU0170899867.USD","IE00BBT3K403.USD","BK4585","IE00B3T34201.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","SG9999013999.USD","OZEM","LU0306807586.USD","SG9999002224.SGD","IE00BLSP4452.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670426474","title":"Pfizer’s RSV Revaccination Trial Targets Durable Booster Revenue in High‑Risk Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2670426474","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670426474?lang=en_us&edition=fundamental","pubTime":"2026-09-26 00:30","pubTimestamp":1790353857,"startTime":"0","endTime":"0","summary":"Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a phase 3 study called “A Study to Learn About ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-rsv-revaccination-trial-targets-durable-booster-revenue-in-highrisk-adults?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-rsv-revaccination-trial-targets-durable-booster-revenue-in-highrisk-adults?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1057294990.SGD","LU1883839398.USD","SGXZ57979304.SGD","SG9999011175.SGD","IE00B19Z3581.USD","LU0456855351.SGD","SG9999013999.USD","LU0122379950.USD","BK4599","LU1894683264.USD","BK4585","LU1066051498.USD","LU0321505868.SGD","LU2596442595.SGD","BK4588","BK4007","LU0321505439.SGD","BK4533","IE00B3T34201.USD","BK4581","IE00BLSP4452.SGD","LU0234572021.USD","BK4592","SG9999001176.SGD","SG9999003800.SGD","LU0868494617.USD","LU0306807586.USD","LU0225771236.USD","LU0306806265.USD","LU0985481810.HKD","BK4568","PFE","BK4534","OZEM","SG9999002232.USD","IE00BLSP4239.USD","LU0170899867.USD","LU1894683348.USD","LU1066053197.SGD","SG9999002224.SGD","BK4550","IE00B19Z3B42.SGD","LU0289739699.SGD","IE00BBT3K403.USD","LU0225284248.USD","LU1023059063.AUD","IE0002270589.USD","SG9999001176.USD","LU0058720904.USD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670242653","title":"AstraZeneca Advances Friday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2670242653","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670242653?lang=en_us&edition=fundamental","pubTime":"2026-09-26 00:09","pubTimestamp":1790352540,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.AstraZeneca PLC  shares rallied 1.23% to GBP125.52 Friday, on what proved to be an all-around positive ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443622.USD","LU2237443382.USD","LU0889565916.HKD","LU2237443895.HKD","LU0432979614.USD","AZNH","LU0320765992.SGD","LU2456880835.USD","LU1829250122.USD","LU0310800379.SGD","LU2468319806.SGD","BK4568","LU2462157665.USD","LU0289739699.SGD","LU2237443465.HKD","BK4585","LU1267930573.SGD","LU0058720904.USD","BK4588","AZN","LU0109394709.USD","IE00B3T34201.USD","BK4007","LU0708994859.HKD","LU0128525929.USD","LU2089984988.USD","LU2237443549.SGD","LU0029864427.USD","LU2417539215.USD","LU2236285917.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670425143","title":"Innovation is Driving a New Bull Market in Biotech. 16 Ways to Play It, from Our Roundtable Experts.","url":"https://stock-news.laohu8.com/highlight/detail?id=2670425143","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670425143?lang=en_us&edition=fundamental","pubTime":"2026-09-25 23:39","pubTimestamp":1790350740,"startTime":"0","endTime":"0","summary":"A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","LU1069347547.HKD","LU0098860793.USD","LU0234572021.USD","LU2468319806.SGD","LU2112291526.USD","LU0965509101.SGD","LU2357627491.SGD","LU0965509283.SGD","LU0211331839.USD","IE00BJT1NW94.SGD","LU0289961442.SGD","PAWZ","LU0130517989.USD","IE0009355771.USD","LU1116320737.USD","IBB","LU1037948541.HKD","LU0320765489.SGD","LU0124676726.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU0472753341.HKD","LU1037948897.HKD","LU0477156953.USD","LU0511384066.AUD","LU1116320901.HKD","LU1066051498.USD","SG9999015341.SGD","MRNX","LU0006306889.USD","LU0072461881.USD","JDOC","LU0965509010.AUD","LU1162221912.USD","LU1974910355.USD","BK4532","IE00BBT3K403.USD","SG9999002224.SGD","LU1093756325.SGD","LU0265550359.USD","SG9999001440.SGD","LU0868494708.USD","LU0648001328.SGD","LU2491049909.HKD","LU1983299246.USD","MRK","IE000M9KFDE8.USD","LU1585245621.USD","RXL","LU1035773651.USD","LU1430594728.SGD","LU1571399168.USD","LU1699723380.USD","LU2433249047.HKD","LU0289739343.SGD","LU1989771016.USD","LU1989772923.USD","LU0823416689.USD","IE00B2B36J28.USD","BK4568","IE00B4R5TH58.HKD","LU2361045086.USD","SG9999014559.SGD","IYH","SGXZ57979304.SGD","LU2106854487.HKD","MRNA","LU2023250504.SGD","XBI","LU0122379950.USD","LU0861579265.USD","BK4534","BMED","LU0106261372.USD","LU0289739699.SGD","WDNA","IHE","LU0069063385.USD","LU1066051225.USD","XLV","SG9999001176.SGD","TRUH","HRTS","IDNA","LU1934455194.USD","VHT","IE00BLSP4452.SGD","BK4550","LU1291159041.SGD","IE00BLSP4239.USD","LU1023059063.AUD","BK4585","BK4139","LU2360032135.SGD","LU1923622614.USD","SG9999014542.SGD","LU1057294990.SGD","PPH","LU1093756168.USD","IE0002141913.USD","LU0203347892.USD","LU2491050154.USD","LU2361044949.HKD","LU1061106388.HKD","LU0057025933.USD","LU1941712348.USD","BK4533","LU1934455277.USD","BK4548","LGHT","LU0432979614.USD","LU0965508806.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU1032466523.USD","LU0868494617.USD","SG9999013999.USD","LU0238689110.USD","LU0058720904.USD","LU0942090050.USD","BK4501","LU0130102774.USD","MRNY","LU0208291251.USD","GDOC","IE00BFTCPJ56.SGD","LU1934455863.HKD","LU1917777945.USD","SG9999001176.USD","LU1989772840.SGD","LU0266013472.USD","BK4516","LU2125909593.SGD","FTXH","LU2361044865.SGD","GNOM","LU0689626769.HKD","SG9999015358.SGD","LU2125154935.USD","LU0985320562.USD","IXJ","LU0162691827.USD","LU2125154778.USD","BK4007","LU0320765646.SGD","LU1941712264.USD","LU0265550946.USD","LU2023250843.SGD","SG9999014567.USD","BK4559","SG9999014575.USD","LU1201861249.SGD","LU2491050071.SGD","BK4581","SG9999002232.USD","BK4551","LU0070302665.USD","BK4588","LU0980610538.SGD","LU2089984988.USD","LU2461242641.AUD","IE00BN8TJ469.HKD","LU2324357040.USD","LU0859254822.USD","LU1929549753.HKD","LU2125909247.SGD","LU1066051811.HKD","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670142531","title":"European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2670142531","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670142531?lang=en_us&edition=fundamental","pubTime":"2026-09-25 23:15","pubTimestamp":1790349322,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking modestly higher late Friday morning, increasing 0.31% to 1,915.69 on the S&P Europe Select ADR Index, which is down 1.1% for the week.From continental Europe, the gainers were led by semiconductor company Sequans Communications  and medical device maker EDAP TMS , which rose 4% and 2.2% respectively. They were followed by biotech firm Evaxion  and biopharmaceutical company Grifols , which increased 2.3% and 2.2% respectively.The decliners from continental Europe were led by accommodations booking site trivago  and petroleum refiner Equinor , which dropped 1.4% and 1.3% respectively. They were followed by biotech firm BioNTech  and internet browser company Opera , which lost 0.5% and 0.1% respectively.The gainers from the UK were led by software firm Endava  and communications company WPP , which advanced 9.1% and 2.7% respectively. They were followed by lenders Lloyds Banking Group  and Barclays , which in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVAX","DAVA.AU","BK4007","LU0648005311.SGD","WPP","BK4141","BK4588","LFGY","BK4521","BK4548","BK4585","EPV","BK4077","BK4201","BK4551","BK4139","AFG","BCYC","AKTX","BK4568","WPP.AU","OPRA","LYG","FOCL","NCNA","BK4134","BNTX","BK4207","BCS","TRVG","IEUR","BK4535","GRFS","BK4009","LU0084288595.USD","BK4117","BK4082","BK4107","DAVA","AMRN","EQNR","SQNS","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670447855","title":"Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas","url":"https://stock-news.laohu8.com/highlight/detail?id=2670447855","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670447855?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:49","pubTimestamp":1790336940,"startTime":"0","endTime":"0","summary":"Shares of Ocugen ticked higher after its treatment for retinitis pigmentosa, or RP, a type of genetic eye disorder, got provisional approval and priority designation from regulators in the Bahamas.The stock was up 2.9% to $1.03 in premarket trading on Friday. At Thursday's market close, shares were down 26% year to date.Ocugen said it got the approval for OCU400 from the Larta Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs in the Bahamas.The biotechnology company plans to treat the first RP patient with OCU400 within 90 days following full Larta approval.OCU400 is currently in Phase 3 development, targeting a broad RP indication from early- to late-stage disease and pediatric to adult patients.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OCGN","BK4563","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670427334","title":"Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study","url":"https://stock-news.laohu8.com/highlight/detail?id=2670427334","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670427334?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:35","pubTimestamp":1790336153,"startTime":"0","endTime":"0","summary":"Johnson & Johnson announced that Tremfya met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reducti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-says-tremfya-met-endpoints-in-phase-4-star-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-says-tremfya-met-endpoints-in-phase-4-star-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHLC","GDOC","JDOC","LU1674673428.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","LU0098860793.USD","LU1244550494.USD","LU1732799900.SGD","IE00BLSP4239.USD","IXJ","LU1221951129.SGD","IE000M9KFDE8.USD","LU1228905037.USD","LU1066053197.SGD","LU1894683264.USD","TRUH","JNJ","LU1280957306.USD","PJP","IYH","LU0738911758.USD","LU0889566641.SGD","LU1496350502.SGD","RXL","VHT","LU0203347892.USD","LU1057294990.SGD","LU1032955483.USD","LU0289961442.SGD","LU1066051498.USD","LU1196500208.SGD","LU1551013342.USD","IE00BKVL7J92.USD","LU1003077747.HKD","BMED","LU0661504455.SGD","LU0820561909.HKD","FTXH","XLV","LU1261432733.SGD","BK4559","SGXZ57979304.SGD","IHE","LU0820562030.AUD","BK4568","LU1145028129.USD","SG9999002224.SGD","IE00BZ1G4Q59.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670421704","title":"Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2670421704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670421704?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:30","pubTimestamp":1790335800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nTUA659LC0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066053197.SGD","VHT","LU2403377893.USD","BK4532","LU0949170772.SGD","XLV","IE00BBT3K403.USD","PJP","JNJ","FHLC","IE0001KFT4U8.USD","LU2896262040.SGD","SGXZ57979304.SGD","BK4568","LU0320765646.SGD","SGXZ80539844.SGD","LU0162691827.USD","GDOC","LU2236285917.USD","MEDX","LU0289961442.SGD","LU1196500208.SGD","LU2756315318.SGD","IE00B19Z3B42.SGD","IE000MB6IJN5.SGD","IE00BJJMRZ35.SGD","LU0098860793.USD","IHE","LU1244550577.SGD","LU0661504455.SGD","JDOC","BK4588","IE000M9KFDE8.USD","LU0820561818.USD","LU0345770993.USD","LU1914381329.SGD","LU1066051225.USD","IXJ","RXL","TRUH","LU1032466523.USD","IYH","BMED","LU1551013342.USD","LU2089984988.USD","BK4007","LU1929549753.HKD","FTXH","LU0122379950.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442334","title":"Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442334","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442334?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:02","pubTimestamp":1790334153,"startTime":"0","endTime":"0","summary":"BRIEF-Single Infusion Of Carvykti Delivered Five-Year Treatment-Free Remissions In 50% Of Patients In Early Line Relapsed/Refractory Multiple MyelomaSept 25 (Reuters)-Johnson & JohnsonJNJ.N:SINGLE INF","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45G1G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF631.EUR","FHLC","LU2602419157.SGD","IE00B1BXHZ80.USD","LU0057025933.USD","VHT","BK4568","IXJ","LU1196500208.SGD","LU1228905540.USD","XLV","IE00B19Z3581.USD","IHE","PJP","SGXZ57979304.SGD","JNJ","LU0345770308.USD","JDOC","LU0689472784.USD","LU0124676726.USD","LU1894683348.USD","IE00B3T34201.USD","LU0882574055.USD","IE00BBT3K403.USD","LU0072461881.USD","SG9999001440.SGD","LU0426417589.USD","FTXH","LU0640476718.USD","MEDX","LU0545562505.USD","LU1496350502.SGD","IE00BLSP4452.SGD","GDOC","IE000WAW04H5.SGD","BMED","TRUH","LU0689626769.HKD","LU0511384066.AUD","IYH","LU2213496289.HKD","LU1032955483.USD","IE00BFXG1179.USD","BK4588","LU0943347566.SGD","LU0545039389.USD","IE00BN8TJ469.HKD","IE0002270589.USD","RXL","LU0345769128.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670423374","title":"Ocugen Wins Provisional Approval for Ocu400 in Bahamas Under LARTA Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2670423374","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670423374?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:02","pubTimestamp":1790334143,"startTime":"0","endTime":"0","summary":"Ocugen wins provisional approval for OCU400 in Bahamas under LARTA pathwayOcugen won provisional approval, priority designation in The Bahamas for OCU400 modifier gene therapy in retinitis pigmentosa.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDLbnh78m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","NDAQ","IE00BQXX3C00.GBP","LU2210150020.SGD","IE00B64PRP62.GBP","BK4563","IE00BQXX3F31.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","BCDF","SG9999014021.USD","BK4568","BK4585","LU2095319765.USD","SG9999014039.USD","BK4139","IE00B3QW5Z07.USD","LU0314104364.USD","OCGN","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442338","title":"Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in the Bahamas to Provide Ocu400 to Patients for Treatment of Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442338","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442338?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:02","pubTimestamp":1790334120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nTUA2LDD5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","OCGN","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670866442","title":"C4 Therapeutics Says Cemsidomide-Elranatamab Phase 1b Trial Clears 75 Μg Dose as Safe in Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2670866442","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670866442?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:00","pubTimestamp":1790334030,"startTime":"0","endTime":"0","summary":"C4 Therapeutics says cemsidomide-elranatamab Phase 1b trial clears 75 g dose as safe in multiple myelomaC4 Therapeutics presented new biomarker results at the 23rd International Myeloma Society annual","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL3pTpzf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","OZEM","CCCC","LU0306807586.USD","BK4007","IE00B3T34201.USD","LU1057294990.SGD","LU1894683348.USD","IE000M9KFDE8.USD","BK4592","LU0122379950.USD","LU0306806265.USD","IE00BLSP4239.USD","BK4550","BK4534","LU1883839398.USD","LU0170899867.USD","LU0868494617.USD","LU1023059063.AUD","SG9999001176.SGD","LU0225284248.USD","BK4588","BK4581","LU0321505868.SGD","LU1066051498.USD","PFE","IE00BLSP4452.SGD","IE00B19Z3B42.SGD","LU0058720904.USD","SG9999013999.USD","BK4568","LU0985481810.HKD","LU1894683264.USD","BK4139","SG9999002232.USD","IE0002270589.USD","BK4533","LU2596442595.SGD","LU0321505439.SGD","LU0456855351.SGD","IE00BBT3K403.USD","SG9999002224.SGD","SG9999011175.SGD","SG9999001176.USD","LU0234572021.USD","BK4599","LU0289739699.SGD","LU1066053197.SGD","IE00B19Z3581.USD","BK4585","LU0225771236.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442867","title":"Moderna (MRNA) Receives a Hold from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442867","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442867?lang=en_us&edition=fundamental","pubTime":"2026-09-25 18:56","pubTimestamp":1790333800,"startTime":"0","endTime":"0","summary":"Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday and set a price target of $45.00. The company’s shares closed yester...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/moderna-mrna-receives-a-hold-from-bernstein-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/moderna-mrna-receives-a-hold-from-bernstein-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","WDNA","BK4532","BK4534","BK4568","BK4551","LGHT","BK4139","BK4548","IDNA","MRNX","BK4588","MRNA","BK4533","BK4585","BK4501","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670448074","title":"AstraZeneca sBLA for Imfinzi combination accepted, granted Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2670448074","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670448074?lang=en_us&edition=fundamental","pubTime":"2026-09-25 18:00","pubTimestamp":1790330414,"startTime":"0","endTime":"0","summary":"AstraZeneca’s (AZN) supplemental Biologics License Application, or sBLA, for Imfinzi in combination with enfortumab vedotin has been accepted by th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-sbla-for-imfinzi-combination-accepted-granted-priority-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-sbla-for-imfinzi-combination-accepted-granted-priority-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443978.SGD","LU2468319806.SGD","IE00B3T34201.USD","LU2417539215.USD","LU0289739699.SGD","LU2236285917.USD","LU0128525929.USD","LU0320765992.SGD","BK4568","LU1267930573.SGD","LU2456880835.USD","LU0432979614.USD","LU0029864427.USD","AZNH","LU2237443622.USD","LU0708994859.HKD","LU2237443895.HKD","LU2237443549.SGD","BK4585","BK4007","LU2237443465.HKD","LU2462157665.USD","BK4588","LU0889565916.HKD","LU0109394709.USD","LU0310800379.SGD","LU0058720904.USD","LU2089984988.USD","LU2237443382.USD","LU1829250122.USD","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670445225","title":"AstraZeneca Gets US FDA Priority Review for Investigative Bladder Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670445225","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670445225?lang=en_us&edition=fundamental","pubTime":"2026-09-25 15:48","pubTimestamp":1790322524,"startTime":"0","endTime":"0","summary":"AstraZeneca  said Friday the US Food and Drug Administration granted priority review to its application for an Imfinzi combination therapy to treat muscle-invasive bladder cancer.The treatment is intended for patients who cannot or choose not to receive cisplatin-based chemotherapy.The submission is based on a phase 3 trial, which showed the perioperative therapy delivered event-free and overall survival improvements compared with bladder removal surgery with or without approved secondary treatments, the company said.AstraZeneca said the FDA is expected to make a regulatory decision in Q4.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1829250122.USD","LU2237443895.HKD","LU2468319806.SGD","LU0310800379.SGD","LU2237443382.USD","AZNH","BK4585","LU2462157665.USD","LU0320765992.SGD","LU2236285917.USD","LU2237443978.SGD","LU0889565916.HKD","LU0432979614.USD","LU2237443622.USD","LU2089984988.USD","LU2237443465.HKD","AZN","LABU","LU2237443549.SGD","LU2456880835.USD","IE00B3T34201.USD","LU0128525929.USD","LU2417539215.USD","LU0058720904.USD","BK4588","LU0109394709.USD","BK4568","LU0289739699.SGD","BK4007","LU0029864427.USD","LU1267930573.SGD","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670417369","title":"INLIF Stock Is Trending: Here's Why it Skyrocketed Over 93% After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2670417369","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670417369?lang=en_us&edition=fundamental","pubTime":"2026-09-25 11:49","pubTimestamp":1790308178,"startTime":"0","endTime":"0","summary":"INLIF shares soared 93% after hours Thursday following strong first-half revenue growth and a return to profitability.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/09/61988300/inlif-stock-jumps-93-percent-after-hours-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","BK4150","IDNA","BK4551","LGHT","RSI","BK4534","BK4532","BK4588","MRNA","MRNY","BK4568","BK4501","BK4139","BETZ","BK4533","BK4548","ODDZ","BK4161","ODDS","INLF","WDNA","BK4585","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670137914","title":"Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2670137914","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670137914?lang=en_us&edition=fundamental","pubTime":"2026-09-25 05:25","pubTimestamp":1790285100,"startTime":"0","endTime":"0","summary":"DJ Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Inovio Pharmaceuticals Inc.  slipped 3.20% to $1.21 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index  rising 0.01% to 26,939.37 and the Dow Jones Industrial Average  falling 0.31% to 51,349.98.This was the stock's second consecutive day of losses.Inovio Pharmaceuticals Inc. closed 55.51% below its 52-week high of $2.72, which the company reached on December 17th.The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson  rose 0.56% to $270.68, Statera Biopharma Inc.  remained unchanged, and Pfizer Inc.  rose 0.82% to $28.41.Trading volume  remained 1.4 million below its 50-day average volume of 4.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 24, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INO","BK4583","BK4568"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":8,"totalSize":237,"code":"91000000","status":"200"}]}}